Market Overview

Alexion Spikes As Company Hires Goldman Sachs (ALXN)

Related ALXN
UPDATE: 8-K from Alexion Pharma Shows FDA Issued Form 483 at Aug. Inspection of Site, Does Not Expect Material Financial Effect Related to FDA Concern
Alexion Initiates Multinational Registration Trial of Eculizumab for Prevention of DGF after Kidney Transplantation

Shares of Alexion (NASDAQ: ALXN) spiked higher when Bloomberg reported that the pharmaceutical company will be working with Goldman Sachs (NYSE: GS) on a potential takeover by Roche (OTC: RHHBY).

Shares of Alexion jumped as high as $120.48, or 10.2 percent on the news. More than 2.5 million shares have already been traded, compared to the average of 2.03 million.

A previous offer from Roche was rejected, but Alexion will be working with Goldman Sachs in the case that Roche raises their offer to a level the pharmaceutical company finds appealing.

Bloomberg reported that Roche is interested in both the company’s blood medication and pipeline.

Analysts will likely review the company in the near future.

Posted-In: Alexion Goldman Sachs Pharmaceutical RocheNews Offerings Hot Best of Benzinga

 

Related Articles (ALXN + GS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters